Press Releases

Archives: Search / 2017

2016201520142013201220112010200920082007

Jul 26, 2017
- First antiepileptic drug (AED) to apply FDA's regulatory pathway of extrapolation for monotherapy use; FDA proposed using this pathway to get monotherapy options to patients sooner

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for FYCOMPA® (perampanel) CIII as monotherapy use...

More
Jul 25, 2017
- Filing based on positive pivotal Phase 3 trial demonstrating non-inferior overall survival compared to sorafenib

Eisai Inc. today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the first-line use of lenvatinib (marketed as Lenvima®), the...

More
Jul 17, 2017

Eisai Inc. announced today the presentation of eight posters, including safety data on three different compounds in its Alzheimer's disease portfolio, at the Alzheimer's Association International...

More
Jun 21, 2017
Lorcaserin Phase IIIb/IV Outcomes Study Assesses Incidence of Major Adverse Cardiovascular Events (MACE) in Patients with Overweight or Obesity

Eisai Inc. today announced that the ongoing investigational CAMELLIA-TIMI 61 study of lorcaserin (marketed as BELVIQ® CIV) will continue as planned, based on the recommendation of an independent...

More
Jun 4, 2017
- Lenvatinib is the first systemic therapy to demonstrate non-inferiority to sorafenib in the primary efficacy endpoint of overall survival

Eisai Inc. today announced results from the REFLECT study (Study 304), a Phase 3 trial evaluating lenvatinib (marketed as Lenvima®), the company's multiple receptor tyrosine kinase inhibitor...

More
Jun 3, 2017
- Interim results of first evaluable cohort (metastatic endometrial cancer) of Study 111, the Phase 1b/2 trial evaluating lenvatinib in combination with pembrolizumab in selected solid tumors, to be presented at 2017 ASCO Annual Meeting

Eisai Inc. today announced interim results from the first evaluable cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as Lenvima®), a multiple receptor tyrosine kinase...

More
May 31, 2017

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., and Johns Hopkins University announced today that they have extended their drug discovery collaboration...

More
May 30, 2017

Eisai Inc., the U.S. subsidiary of Tokyo, Japan-based Eisai Co., Ltd., announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research...

More
May 18, 2017
- Full results of Study 304, a Phase 3 study evaluating the safety and efficacy of Lenvima® (lenvatinib) as compared to sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma, to be presented in an oral presentation on Sunday, June 4 at 8:12 a.m. CDT

Eisai Inc. announced today the presentation of new data and analyses at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3 – 7 in Chicago. The data to be presented...

More
Apr 27, 2017
Data to be Presented at the American Academy of Neurology "Best Of" Epilepsy Session

Eisai Inc. announced today the presentation of results from a new meta-analysis of published clinical trials showing that the effect of adjunctive antiepileptic drug (AED) treatment versus placebo...

More
Apr 19, 2017
5-YEAR ANNIVERSARY OF LONDON DECLARATION ON NEGLECTED TROPICAL DISEASES

Eisai Inc. announced today that its parent company Tokyo, Japan-based Eisai Co., Ltd. has pledged the continuing support of its initiatives for the elimination of lymphatic filariasis (LF), a...

More
Apr 13, 2017
Meta-analysis on the extrapolation of adult antiepileptic drug efficacy data, including perampanel, to pediatric patients to be featured in "Best Of" oral presentation panel

Eisai Inc. announced today that eight poster presentations featuring data on the safety and efficacy of perampanel (marketed as FYCOMPA® CIII) in a range of seizure types will be presented at the...

More
Mar 28, 2017
Research to be presented spans four of the Company's investigational and marketed oncology therapies, both as single agents and in combination

Eisai Inc. announced today 13 presentations of clinical and preclinical research at the American Association for Cancer Research (AACR) 2017 Annual Meeting, April 1 – 5, 2017 in Washington, D.C....

More
Mar 23, 2017

Eisai Inc. is pleased to announce that it will be launching the latest "Medikidz Explain Epilepsy," book as part of their participation at the Epilepsy Foundation's National Walk for Epilepsy on...

More
Mar 17, 2017

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Kirk Shepard, MD, as Senior Vice President, Global Medical Affairs of the Oncology...

More
Jan 25, 2017

Eisai Inc. today announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company's multiple receptor tyrosine kinase inhibitor, lenvatinib...

More
Jan 18, 2017
Accelerating Access to Health Care in Low and Lower-Middle Income Countries

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that it is participating in Access Accelerated, a global partnership to advance access to non-communicable...

More
Jan 4, 2017

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. (collectively, "Eisai"), announced today that it has reached an agreement with Arena Pharmaceuticals, Inc. to revise the November...

More
Dec 19, 2016

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has received regulatory approval from the Brazilian Health...

More
Dec 12, 2016

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of two posters highlighting the latest data on elenbecestat (development code: E2609), its...

More
 

print email rss